Skip to content
Screener

Protagonist Therapeutics PTGX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$4.7MMiss by $10.2M
EPS-$0.62Miss by $0.03
Revenue estimate$14.9M
EPS estimate-$0.59

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$240.1M
EPS estimate$2.43

Financials

Q3 2025

Income statement

See full
Revenue$4.7M+0.8%
Operating income-$46.4M-12.0%
Net income-$39.3M-18.5%
EPS (diluted)-$0.62-14.8%

Balance sheet

See full
Cash & equivalents$113.7M-13.3%
Total debt$10.7M-1.4%
Total equity$645.4M+21.3%
Total assets$701.7M+16.2%

Cash flow

See full
CapEx$88.0K-88.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$4.13B+49.8%
Enterprise value$4.03B+52.7%
P/E90×—
P/S19.8×+11.2×

Profitability

See full
Operating margin9.1%—
Net margin21.9%—

Returns & leverage

See full
Return on equity7.8%—
Debt / equity0×0.0×
Current ratio13×+2.4×

FAQ

When did Protagonist Therapeutics report Q3 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Protagonist Therapeutics's Q3 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $4.7M and eps of $-0.62 for Q3 2025.
Did Protagonist Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $14.9M by $10.2M. EPS missed the consensus estimate of $-0.59 by $0.03.
How did Protagonist Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.8% from $4.7M a year earlier and eps declined 14.8% from $-0.54.
Where can I find Protagonist Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-107753) and the 10-Q periodic report (0001104659-25-107816) directly on SEC EDGAR. The filing index links above go to sec.gov.